Below are the most recent publications written about "Tuberculosis, Multidrug-Resistant" by people in Profiles.
-
Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH. Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis. Am J Respir Crit Care Med. 2020 06 15; 201(12):1579-1580.
-
Wasserman S, Furin J. Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with inhA Mutations. Am J Respir Crit Care Med. 2020 06 01; 201(11):1331-1333.
-
Chakaya JM, Marais B, du Cros P, Ntoumi F, Mfinanga S, Kapata N, Hasnain SE, Nathavitharana R, Zumla A. Programmatic versus personalised approaches to managing the global epidemic of multidrug-resistant tuberculosis. Lancet Respir Med. 2020 04; 8(4):334-335.
-
Furin J, Loveday M, Hlangu S, Dickson-Hall L, le Roux S, Nicol M, Cox H. "A very humiliating illness": a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa. BMC Public Health. 2020 Jan 17; 20(1):76.
-
Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 11 15; 200(10):e93-e142.
-
Becerra MC, Huang CC, Lecca L, Bayona J, Contreras C, Calderon R, Yataco R, Galea J, Zhang Z, Atwood S, Cohen T, Mitnick CD, Farmer P, Murray M. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019 10 24; 367:l5894.
-
Ng KCS, Supply P, Cobelens FGJ, Gaudin C, Gonzalez-Martin J, de Jong BC, Rigouts L. How Well Do Routine Molecular Diagnostics Detect Rifampin Heteroresistance in Mycobacterium tuberculosis? J Clin Microbiol. 2019 11; 57(11).
-
Rodriguez CA, Mitnick CD, Franke MF. Value of observational data for multidrug-resistant tuberculosis. Lancet Infect Dis. 2019 09; 19(9):930-931.
-
Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir Med. 2019 09; 7(9):820-826.
-
Buziashvili M, Mirtskhulava V, Kipiani M, Blumberg HM, Baliashvili D, Magee MJ, Furin JJ, Tukvadze N, Kempker RR. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia. Int J Tuberc Lung Dis. 2019 09 01; 23(9):1005-1011.